Literature DB >> 10720587

Mechanisms of big endothelin-1-induced diuresis and natriuresis : role of ET(B) receptors.

A Hoffman1, Z A Abassi, S Brodsky, R Ramadan, J Winaver.   

Abstract

Endothelin-1 (ET-1) at high concentrations has marked antidiuretic and antinatriuretic activities, whereas its precursor, big endothelin-1 (big ET-1), has surprisingly potent diuretic and natriuretic actions. The mechanisms underlying the excretory effects of big ET-1 have not been fully elucidated. To explore these mechanisms, we examined the effects of a highly selective ET(B) antagonist (A-192621.1), a calcium channel blocker (verapamil), a nitric oxide synthase inhibitor (N-nitro-L-arginine methyl ester [L-NAME]), and a cyclooxygenase inhibitor (indomethacin) on the systemic and renal actions of big ET-1 in anesthetized rats. An intravenous bolus injection of incremental doses of big ET-1 (0.3, 1. 0, and 3.0 nmol/kg) produced a significant hypertensive effect that was dose dependent and prolonged (from 113+/-7 mm Hg to a maximum of 148+/-6 mm Hg). The administration of big ET-1 induced marked diuretic and natriuretic responses (urinary flow rate increased from 8.5+/-1 to 110+/-14 microL/min, and fractional excretion of sodium increased from 0.38+/-0.13% to 7.51+/-1.24%). Glomerular filtration rate and renal plasma flow significantly decreased only at the highest dose of big ET-1. Pretreatment with A-192621.1 (3 mg/kg plus 3 mg. kg(-1). h(-1)) significantly abolished the diuretic (17+/-5 microL/min to a maximum of 19+/-3 microL/min) and natriuretic (0. 29+/-0.1% to a maximum of 1.93+/-0.37%) responses induced by big ET-1. Moreover, A-192621.1 potentiated the decline in glomerular filtration rate and renal plasma flow and the increase in mean arterial blood pressure produced by the low doses of big ET-1. Similar to A-192621.1, pretreatment with a nitric oxide synthase inhibitor (L-NAME, 10 mg/kg plus 5 mg. kg(-1). h(-1)) significantly and comparably reduced the diuretic and natriuretic actions of big ET-1 and augmented the hypoperfusion/hypofiltration and systemic vasoconstriction induced by high doses of the peptide. Pretreatment with verapamil (2 mg. kg(-1). h(-1)) slightly inhibited the diuretic/natriuretic effects of the high-dose big ET-1 and completely prevented the increase in mean arterial blood pressure provoked by the peptide. Unlike verapamil and L-NAME, only indomethacin administration was associated with significant natriuretic/diuretic responses and did not influence the pressor effect and renal actions of big ET-1. Taken together, these results suggest that big ET-1-induced diuretic and natriuretic responses are mediated mainly by stimulation of nitric oxide production coupled to ET(B) receptor subtype activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720587     DOI: 10.1161/01.hyp.35.3.732

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  14 in total

Review 1.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

2.  Regulation of vascular contractility and blood pressure by the E2F2 transcription factor.

Authors:  Junlan Zhou; Yan Zhu; Min Cheng; Deepika Dinesh; Tina Thorne; Kian Keong Poh; Dongxu Liu; Chantal Botros; Yao Liang Tang; Nichole Reisdorph; Raj Kishore; Douglas W Losordo; Gangjian Qin
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

Review 3.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 4.  Endothelial dysfunction: a strategic target in the treatment of hypertension?

Authors:  Eva H C Tang; Paul M Vanhoutte
Journal:  Pflugers Arch       Date:  2010-02-02       Impact factor: 3.657

5.  Role of GRK4 in the regulation of the renal ETB receptor in hypertension.

Authors:  Yang Yang; Meixiang Li; Xue Zou; Caiyu Chen; Shuo Zheng; Chunjiang Fu; Ken Chen; Pedro A Jose; Cong Lan; Yukai Liu
Journal:  FASEB J       Date:  2020-07-20       Impact factor: 5.191

6.  Endothelin mediates some of the renal actions of acutely administered angiotensin II.

Authors:  A Riggleman; J Harvey; C Baylis
Journal:  Hypertension       Date:  2001-07       Impact factor: 10.190

Review 7.  Endothelin antagonists in hypertension and kidney disease.

Authors:  Kevin E C Meyers; Christine Sethna
Journal:  Pediatr Nephrol       Date:  2012-10-16       Impact factor: 3.714

8.  Endothelin-1, big endothelin-1, and nitric oxide in patients with chronic renal disease and hypertension.

Authors:  Ivanka Mikulić; József Petrik; Kresimir Galesić; Zeljko Romić; Ivana Cepelak; Monika Zeljko-Tomić
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

9.  Aldosterone modulates steroid receptor binding to the endothelin-1 gene (edn1).

Authors:  Lisa R Stow; Michelle L Gumz; I Jeanette Lynch; Megan M Greenlee; Alicia Rudin; Brian D Cain; Charles S Wingo
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

10.  The association of endothelin-1 with markers of oxidative stress in a biethnic South African cohort: the SABPA study.

Authors:  Christine Susara du Plooy; Catharina Martha Cornelia Mels; Hugo Willem Huisman; Ruan Kruger
Journal:  Hypertens Res       Date:  2016-09-29       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.